In Conversation: John Mumm, Chief Executive Officer, Deka Biosciences

Published on :

John Mumm is a serial biotechnology entrepreneur who, as a young researcher, demonstrated the importance of the cytokine, interleukin -10 (IL-10), in activating the immune system to destroy tumors. That research led to the use of Pegylated IL-10 to treat patients with pancreatic cancer and other solid tumors through his work at ARMO Biosciences, a company he founded and was later acquired by Eli Lilly in 2018.

Ascentage Pharma and Innovent Biologics Reach Multifaceted Strategic Agreement Totaling $245M

Published on :

Ascentage Pharma (6855.HK), a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics (1801.HK, “Innovent”), today announced a multifaceted strategic collaboration.